Last reviewed · How we verify
DFP-10917
DFP-10917 is a small molecule that targets the SGLT2 receptor.
DFP-10917 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | DFP-10917 |
|---|---|
| Sponsor | Delta-Fly Pharma, Inc. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, DFP-10917 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This makes it a potential treatment for type 2 diabetes. Its exact mechanism of action is not fully understood, but it is believed to work by reducing glucose reabsorption in the kidneys.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Vomiting
Key clinical trials
- Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage (PHASE3)
- DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia (PHASE1, PHASE2)
- Trial of DFP-14927 in Advanced Solid Tumors (PHASE1)
- Phase I/II Study of DFP-10917 in Patients With Acute Leukemia (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |